Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days the report can be obtained for the MLPA- Lynch syndrome (HNPCC) Deletion/Duplication Analysis Test is typically 14-21 days from the date of sample receipt.

What are the prerequisites for the test MLPA- Lynch syndrome (HNPCC) Deletion/Duplication Analysis Test

  • Patient must have a suspected diagnosis of Lynch syndrome (HNPCC)
  • Confirmation of Lynch syndrome in the family
  • Documentation of microsatellite instability (MSI) or immunohistochemistry (IHC) testing showing loss of expression of one or more MMR proteins
  • Confirmation of Lynch syndrome by germline testing

What are the measure values for the test MLPA- Lynch syndrome (HNPCC) Deletion/Duplication Analysis Test

  • Deletion: 0.7 or less
  • Normal: 0.7 - 1.3
  • Duplication: 1.3 or greater

What does this test MLPA- Lynch syndrome (HNPCC) Deletion/Duplication Analysis Test identify?

MLPA- Lynch syndrome (HNPCC) Deletion/Duplication Analysis Test

The MLPA test for Lynch syndrome (HNPCC) is a genetic test that identifies deletions or duplications in specific genes associated with Lynch syndrome. Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is an inherited condition that increases the risk of developing certain types of cancer, particularly colorectal and endometrial cancer.

The MLPA test specifically looks for deletions or duplications in the genes MLH1, MSH2, MSH6, and PMS2, which are known to be associated with Lynch syndrome. These gene mutations can increase the risk of developing cancer by affecting the body's ability to repair DNA damage and prevent the growth of abnormal cells.

By identifying these genetic mutations, the MLPA test can help healthcare providers determine a person's risk of developing cancer and make informed decisions about screening and prevention strategies. This test is often recommended for individuals with a personal or family history of Lynch syndrome-associated cancers.

Why is this test MLPA- Lynch syndrome (HNPCC) Deletion/Duplication Analysis Test taken?

  • This test is taken to determine if an individual has Lynch syndrome (HNPCC), which is a hereditary condition that increases the risk of developing certain types of cancer.
  • Specifically, the MLPA test is used to detect deletions or duplications in the genes associated with Lynch syndrome, such as MLH1, MSH2, MSH6, and PMS2.
  • Identifying these genetic changes can help healthcare providers assess a person's risk of developing cancer and develop appropriate screening and prevention strategies.
  • Individuals with Lynch syndrome may benefit from earlier and more frequent cancer screenings, as well as potential preventative measures such as surgery or medication.
  • Overall, the MLPA- Lynch syndrome Deletion/Duplication Analysis Test is crucial for diagnosing and managing Lynch syndrome in affected individuals and their families.

No FAQs available.

Customer Google Rating